Osimertinib Mesylate
FDA-approved product (tablet, oral), marketed as Tagrisso.
- Registered studies
- 26
- Lab records
- 0
- Pathogens at ≥40%
- 3 of 4
Chemical structure
Existing / approved use
Documented · FDA, WHO, ChEMBLApproved for
- Cancer
- Neoplasm
- Non-small cell lung carcinoma
Indications ChEMBL records as approved, from FDA and DailyMed labels. Label ↗
- WHO therapeutic group
- Epidermal growth factor receptor (egfr) tyrosine kinase inhibitors
- Anti-infective classification
- Not classified as an anti-infective.
Repurposing investigation
This medicine is being investigated here for AI-predicted antimicrobial activity against M. tuberculosis, MRSA and E. coli. It was surfaced computationally for further investigation; it is not an established treatment for these infections.
AI-predicted activity
AI prediction · nothing measured- MRSA55.0% AI-predicted activityAt or above the ≥40% mark this site uses to surface candidates.
- E. coli43.0% AI-predicted activityAt or above the ≥40% mark this site uses to surface candidates.
- K. pneumoniae29.8% AI-predicted activityBelow the ≥40% mark this site uses to surface candidates.
- M. tuberculosis60.0% AI-predicted activityAt or above the ≥40% mark this site uses to surface candidates.
A model’s estimate of laboratory activity against each pathogen species. It is not clinical effectiveness.
Evidence
Clinical and experimental
Documented evidenceClinical
26registered studies name this medicine, for any condition. See them below.
Experimental
No evidence found
No laboratory measurement against the four pathogens in the ChEMBL records loaded here.
Docking
Computational · nothing measuredDihydrofolate reductase ↗ (E. coli)
Not yet docked: queued in the docking rundetails
KPC-2 carbapenemase ↗ (K. pneumoniae)
Not yet docked: queued in the docking rundetails
Enoyl-ACP reductase (InhA) ↗ (M. tuberculosis)
Not yet docked: queued in the docking rundetails
Dihydrofolate reductase ↗ (MRSA)
Not yet docked: queued in the docking rundetails
AutoDock Vina, one experimentally solved protein per pathogen. This project’s screening target is -7.0 kcal/mol, its own mark rather than a universal cutoff. A docking score is a structural hypothesis, not proof of binding, and requires experimental validation.
Other medicines to investigate
AI prediction · nothing measuredOther repurposing candidates: approved medicines besides Osimertinib Mesylate with AI-predicted activity ≥40% against the chosen pathogen, leaving out existing antimicrobials. They are computational candidates for further investigation, not alternatives and not recommendations.
Sorted by AI-predicted activity, high to low. The order is not a ranking of which medicine is better.
- FurazolidoneExisting use: Other antiinfectives and antiseptics91.4% AI-predicted activityagainst M. tuberculosisLab records exist49 registered studies
- TriflupromazineExisting use: Psychosis90.6% AI-predicted activityagainst M. tuberculosisNo documented evidence found
- ValdecoxibExisting use: Dysmenorrhea, Osteoarthritis, Rheumatic disease and 1 more88.6% AI-predicted activityagainst M. tuberculosisLab records exist31 registered studies
- CelecoxibExisting use: Ankylosing spondylitis, Cancer, Colorectal neoplasm and 15 more87.6% AI-predicted activityagainst M. tuberculosisLab records exist50+ registered studies
- Dorzolamide HydrochlorideExisting use: Glaucoma, Ocular hypertension, Open-angle glaucoma86.8% AI-predicted activityagainst M. tuberculosisLab records exist50+ registered studies
- MethazolamideExisting use: Glaucoma, Open-angle glaucoma85.6% AI-predicted activityagainst M. tuberculosisLab records exist11 registered studies
- AcetazolamideExisting use: Altitude sickness, Angle-closure glaucoma, Congestive heart failure and 5 more85.2% AI-predicted activityagainst M. tuberculosisLab records exist50+ registered studies
- Trifluoperazine HydrochlorideExisting use: Anxiety disorder, Mental or behavioural disorder, Psychosis and 1 more84.6% AI-predicted activityagainst M. tuberculosis1 registered study
- TriclosanExisting use: Phenol and derivatives, Medicated dressings with antiinfectives84.2% AI-predicted activityagainst M. tuberculosisLab records exist50+ registered studies
- NitrofurazoneExisting use: Eye infection, Leishmaniasis, Trypanosomiasis84.0% AI-predicted activityagainst M. tuberculosis8 registered studies
- BrinzolamideExisting use: Glaucoma, Ocular hypertension, Open-angle glaucoma83.8% AI-predicted activityagainst M. tuberculosisLab records exist50+ registered studies
- ZonisamideExisting use: Epilepsy, Focal-onset seizure, Partial epilepsy and 1 more82.8% AI-predicted activityagainst M. tuberculosisLab records exist50+ registered studies
Registered studies
A registration describes a study; it does not establish a positive result.
Phase II Clinical Study to Evaluate the Safety, Tolerability, Pharmacokinetics and Antitumor Activity of ALK202 for Injection in Combination With Drugs in NSCLC Participants.
NCT07603791 · start 2026-06-30
Registered record
- Registry ID
- NCT07603791
- Conditions
- NSCLC (Advanced Non-small Cell Lung Cancer)
- Interventions
- ALK202 for injection; Osimertinib Mesylate Tablets; Ivonescimab Injection; carboplatin injection
- Study type
- INTERVENTIONAL
- Phase
- Phase 2
- Registry status
- Not yet recruiting
- Start
- 2026-06-30
- Completion
- 2028-12-30
- Enrolment
- 252
As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.
ConditionNSCLC (Advanced Non-small Cell Lung Cancer)InterventionALK202 for injection; Osimertinib Mesylate Tablets; Ivonescimab Injection; carboplatin injectionPhasePhase 2Registry statusNot yet recruitingA Study of SYS6010 Combined With Osimertinib Versus Osimertinib Alone as Neoadjuvant Therapy for Patients With EGFR Mutation-positive Resectable Non-squamous Non-small Cell Lung Cancer
NCT07256509 · start 2025-11-30
Registered record
- Registry ID
- NCT07256509
- Conditions
- Non-Small Cell Lung Cancer
- Interventions
- SYS6010; Osimertinib; Pemetrexed; Cisplatin; Carboplatin
- Study type
- INTERVENTIONAL
- Phase
- Phase 2
- Registry status
- Not yet recruiting
- Start
- 2025-11-30
- Completion
- 2032-06-30
- Enrolment
- 120
As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.
ConditionNon-Small Cell Lung CancerInterventionSYS6010; Osimertinib; Pemetrexed; Cisplatin +1 morePhasePhase 2Registry statusNot yet recruitingA Study of SHR-A2102 in Combination With Other Anti-tumor Therapies for Resectable Non-small Cell Lung Cancer
NCT07229729 · start 2025-11-24
Registered record
- Registry ID
- NCT07229729
- Conditions
- Non-small Cell Lung Cancer
- Interventions
- SHR-A2102; Adebrelimab; Paclitaxel; Carboplatin; Alomnertinib Mesilate; Furmonertini Mesilate; Osimertinib Mesylate
- Study type
- INTERVENTIONAL
- Phase
- Phase 2
- Registry status
- Recruiting
- Start
- 2025-11-24
- Completion
- 2029-10
- Enrolment
- 300
As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.
ConditionNon-small Cell Lung CancerInterventionSHR-A2102; Adebrelimab; Paclitaxel; Carboplatin +3 morePhasePhase 2Registry statusRecruitingA Study to Evaluate the Efficacy and Safety of Glumetinib Combined With Osimertinib Mesylate Versus Platinum-based Doublet Chemotherapy in Non-Small Cell Lung Cancer Patients After Resistance to EGFR-TKIs
NCT06829459 · start 2025-04-03
Registered record
- Registry ID
- NCT06829459
- Conditions
- Non-Small Cell Lung Cancer
- Interventions
- Glumetinib; Osimertinib mesylate; Pemetrexed; Cisplatin or carboplatin
- Study type
- INTERVENTIONAL
- Phase
- Phase 3
- Registry status
- Recruiting
- Start
- 2025-04-03
- Completion
- 2029-02-15
- Enrolment
- 350
As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.
ConditionNon-Small Cell Lung CancerInterventionGlumetinib; Osimertinib mesylate; Pemetrexed; Cisplatin or carboplatinPhasePhase 3Registry statusRecruitingGlumetinib Combined With Osimertinib Treatment for Non-Small Cell Lung Cancer Patients
NCT06908772 · start 2025-04-01
Registered record
- Registry ID
- NCT06908772
- Conditions
- Recurrent or Metastatic NSCLC Patients With Classical EGFR Mutations Accompanied by MET Amplification or Overexpression
- Interventions
- Glumetinib Tablets; Osimertinib Mesylate Tablets; Glumetinib Tablets Placebo
- Study type
- INTERVENTIONAL
- Phase
- Phase 2 / Phase 3
- Registry status
- Not yet recruiting
- Start
- 2025-04-01
- Completion
- 2030-01-31
- Enrolment
- 390
As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.
ConditionRecurrent or Metastatic NSCLC Patients With Classical EGFR Mutations Accompanied by MET Amplification or OverexpressionInterventionGlumetinib Tablets; Osimertinib Mesylate Tablets; Glumetinib Tablets PlaceboPhasePhase 2 / Phase 3Registry statusNot yet recruitingA Trial of SHR-A2102 With Other Antitumor Therapies in Advanced Solid Tumors
NCT06895928 · start 2025-03-28
Registered record
- Registry ID
- NCT06895928
- Conditions
- Advanced Solid Tumors
- Interventions
- SHR-A2102; Bevacizumab Injection; Adebelimab Injection; Ametinib Mesylate Tablets; Osimertinib Mesylate Tablets
- Study type
- INTERVENTIONAL
- Phase
- Phase 2
- Registry status
- Recruiting
- Start
- 2025-03-28
- Completion
- 2028-12
- Enrolment
- 400
As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.
ConditionAdvanced Solid TumorsInterventionSHR-A2102; Bevacizumab Injection; Adebelimab Injection; Ametinib Mesylate Tablets +1 morePhasePhase 2Registry statusRecruitingStudy of Precision Treatment for Rare Tumours in China Guided by PDO and NGS
NCT06692491 · start 2025-01-01
Registered record
- Registry ID
- NCT06692491
- Conditions
- Rare Tumour
- Interventions
- Albumin-Bound Paclitaxel; Epirubicin; Gemcitabine; Vinorelbine; Cisplatin; Irinotecan; Fluorouracil; Nivolumab; Pembrolizumab; Durvalumab; Atezolizumab; Sintilimab; Tislelizumab; Camrelizumab; Toripalimab; Serplulimab; Adebrelimab; Envafolimab; Osimertinib; Alectinib; Vemurafenib; Pamiparib; Pyrotinib; Imatinib; Palbociclib; Savolitinib; Entrectinib; Other
- Study type
- INTERVENTIONAL
- Phase
- Phase 2
- Registry status
- Not yet recruiting
- Start
- 2025-01-01
- Completion
- 2029-12-31
- Enrolment
- 200
As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.
ConditionRare TumourInterventionAlbumin-Bound Paclitaxel; Epirubicin; Gemcitabine; Vinorelbine +24 morePhasePhase 2Registry statusNot yet recruitingOsimertinib Combined With Savolitinib in the Treatment of NSCLC With Low Copy Number MET Amplification
NCT07322783 · start 2025-01-01
Registered record
- Registry ID
- NCT07322783
- Conditions
- EGFR Positive Non-small Cell Lung Cancer; MET Amplification
- Interventions
- • Drug: Savolitinib • Drug: Osimertinib Mesylate Tablets
- Study type
- INTERVENTIONAL
- Phase
- Phase 2
- Registry status
- Recruiting
- Start
- 2025-01-01
- Completion
- 2026-12-31
- Enrolment
- 60
As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.
ConditionEGFR Positive Non-small Cell Lung Cancer; MET AmplificationIntervention• Drug: Savolitinib • Drug: Osimertinib Mesylate TabletsPhasePhase 2Registry statusRecruitingA Study Evaluating Furmonertinib Plus Platinum-based Doublet Chemotherapy Versus Osimertinib in Patients With Epidermal Growth Factor Receptor (EGFR) Sensitizing Mutation-Positive Non-squamous Non-Small Cell Lung Cancer (NSCLC) and Brain Metastases
NCT06970639 · start 2024-09-26
Registered record
- Registry ID
- NCT06970639
- Conditions
- NSCLC Patients With Brain Metastasis
- Interventions
- Furmonertinib Mesilate Tablets; Carboplatin Injection; Cisplatin for injection; Pemetrexed Disodium for Injection; Osimertinib Mesylate Tablets
- Study type
- INTERVENTIONAL
- Phase
- Phase 3
- Registry status
- Recruiting
- Start
- 2024-09-26
- Completion
- 2029-09
- Enrolment
- 380
As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.
ConditionNSCLC Patients With Brain MetastasisInterventionFurmonertinib Mesilate Tablets; Carboplatin Injection; Cisplatin for injection; Pemetrexed Disodium for Injection +1 morePhasePhase 3Registry statusRecruitingA Study of BL-B01D1 in Combination With Osimertinib Mesylate Tablets in Patients With Locally Advanced or Metastatic Non-small Cell Lung Cancer
NCT06498986 · start 2024-07-31
Registered record
- Registry ID
- NCT06498986
- Conditions
- Non-small Cell Lung Cancer
- Interventions
- BL-B01D1; Osimertinib Mesylate Tablets
- Study type
- INTERVENTIONAL
- Phase
- Phase 2
- Registry status
- Recruiting
- Start
- 2024-07-31
- Completion
- 2026-08
- Enrolment
- 40
As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.
ConditionNon-small Cell Lung CancerInterventionBL-B01D1; Osimertinib Mesylate TabletsPhasePhase 2Registry statusRecruitingA Study to Evaluate the Efficacy of Osimertinib in Patients With EGFR-sensitive Mutated Non-small Cell Lung Cancer Progression After Receiving Adjuvant Targeted Therapy Following Radical Surgery
NCT06530719 · start 2024-07
Registered record
- Registry ID
- NCT06530719
- Conditions
- Lung Neoplasms; Lung Cancer, Nonsmall Cell
- Interventions
- Osimertinib mesylate
- Study type
- INTERVENTIONAL
- Phase
- Phase 2
- Registry status
- Not yet recruiting
- Start
- 2024-07
- Completion
- 2028-05
- Enrolment
- 54
As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.
ConditionLung Neoplasms; Lung Cancer, Nonsmall CellInterventionOsimertinib mesylatePhasePhase 2Registry statusNot yet recruitingA Phase Ib/II Clinical Study of GH21 Capsules Combined With Osimertinib Mesylate Tablets in Patients With NSCLC
NCT06306456 · start 2024-03-05
Registered record
- Registry ID
- NCT06306456
- Conditions
- Non-Small Cell Lung Cancer With EGFR Mutation
- Interventions
- GH21; Tagrisso
- Study type
- INTERVENTIONAL
- Phase
- Phase 1 / Phase 2
- Registry status
- Recruiting
- Start
- 2024-03-05
- Completion
- 2026-12-31
- Enrolment
- 94
As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.
ConditionNon-Small Cell Lung Cancer With EGFR MutationInterventionGH21; TagrissoPhasePhase 1 / Phase 2Registry statusRecruitingA Study of BL-B01D1 and BL-B01D1 in Combination With Osimertinib Mesylate Tablets in Patients With Locally Advanced or Metastatic Non-small Cell Lung Cancer
NCT05880706 · start 2023-07-19
Registered record
- Registry ID
- NCT05880706
- Conditions
- Non-small Cell Lung Cancer
- Interventions
- BL-B01D1; Osimertinib Mesylate Tablets
- Study type
- INTERVENTIONAL
- Phase
- Phase 2
- Registry status
- Active not recruiting
- Start
- 2023-07-19
- Completion
- 2027-07
- Enrolment
- 198
As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.
ConditionNon-small Cell Lung CancerInterventionBL-B01D1; Osimertinib Mesylate TabletsPhasePhase 2Registry statusActive not recruitingA Study of SKB264 (MK-2870; Sac-TMT) for the Treatment of Participants With Advanced or Metastatic Non-small Cell Lung Cancer (SKB264-II-04) (MK-2870-003)
NCT05816252 · start 2023-04-19
Registered record
- Registry ID
- NCT05816252
- Conditions
- Non-small Cell Lung Cancer
- Interventions
- SKB264; Pembrolizumab; Carboplatin; Osimertinib
- Study type
- INTERVENTIONAL
- Phase
- Phase 2
- Registry status
- Active not recruiting
- Start
- 2023-04-19
- Completion
- 2026-12-30
- Enrolment
- 356
As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.
ConditionNon-small Cell Lung CancerInterventionSKB264; Pembrolizumab; Carboplatin; OsimertinibPhasePhase 2Registry statusActive not recruitingVIC-1911 Combined With Osimertinib for EGFR -Mutant Non-small Cell Lung Cancer
NCT05489731 · start 2022-09-21
Registered record
- Registry ID
- NCT05489731
- Conditions
- Advanced Non-small Cell Lung Cancer
- Interventions
- VIC-1911; Osimertinib Mesylate Tablets
- Study type
- INTERVENTIONAL
- Phase
- Phase 1
- Registry status
- Unknown
- Start
- 2022-09-21
- Completion
- 2024-04-24
- Enrolment
- 72
As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.
ConditionAdvanced Non-small Cell Lung CancerInterventionVIC-1911; Osimertinib Mesylate TabletsPhasePhase 1Registry statusUnknown